摘要近年来的研究发现,磺脲类药物存在具有临床意义的胰腺外作用,且不同磺脲类药物的胰腺外作用机制和靶点存在差异.本文基于现有的基础和临床数据探讨了磺脲类药物胰腺外非降糖作用对2型糖尿病患者临床结局的影响,包括磺脲类药物胰腺外作用对冠状动脉粥样硬化、认知障碍和骨代谢异常相关风险因素,以及长期治疗安全性的影响.总体来看,新型磺脲类药物(如格列美脲)的胰腺外作用与2型糖尿病患者的临床结局改善相关,而不良反应则较小.

abstractsRecent studies revealed a number of interesting extrapancreatic actions of sulfonylureas (SUs),and there existed various mechanisms and targets of extrapancreatic effects among different SUs.We try to explore the impact of extrapancreatic effects on the clinical outcome of patients with type 2 diabetes mellitus (T2DM) based on the data from basic and clinical researches,including the effects of SUs on atherosclerosis,cognitive impairment,risk factors associated with abnormal bone metabolism,as well as the safety of treatment.All together,extrapancreatic effects of novel sulphonylureas (e.g.glimepiride) are associated with the improved clinical outcomes and less adverse effects in patients with T2DM.